Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : PFE (Pfizer) How high will it go? -- Ignore unavailable to you. Want to Upgrade?

To: Uncle Frank who wrote (5691)	9/24/1998 12:41:00 AM
From: BDR	Respond to of 9523

Sept 10 was a busy day: freeedgar.com Item 2. Acquisition or Disposition of Assets The sale of the Schneider Worldwide business -- a part of Pfizer Inc.'s Medical Technology Group -- to Boston Scientific Corporation (BSX) for $2.1 billion in cash, closed on September 10, 1998. The sale was a negotiated, arms-length transaction. Based in Bulach -- near Zurich, Switzerland -- Schneider manufactures and sells stents for a variety of applications, angioplasty devices and accessories. In addition to its global headquarters in Bulach, Schneider maintains facilities in Plymouth, Minnesota; Glens Falls, New York; Aguadilla, Puerto Rico; Miami, Florida; and Tullamore, Ireland. In 1997, Schneider reported sales of approximately $330 million.